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Abstract
Background—Introduction of a universal varicella vaccine program for U.S. children in 1996 
sparked concern that less-frequent exposure to varicella would decrease external boosting of 
immunity to varicella zoster virus and thereby increase incidence of herpes zoster (HZ).
Objective—To determine whether the varicella vaccination program has influenced trends in HZ 
incidence in the U.S. population older than 65 years.
Design—Retrospective study of Medicare claims.
Setting—Medicare, 1992 through 2010.
Participants—2 848 765 beneficiaries older than 65 years.
Measurements—Annual HZ incidence from 1992 through 2010; rate ratios (RRs) for HZ 
incidence by age, sex, and race or ethnicity; and state-level varicella vaccination coverage.
Results—281 317 incident cases of HZ occurred. Age- and sex-standardized HZ incidence 
increased 39% from 10.0 per 1000 person-years in 1992 to 13.9 per 1000 person-years in 2010 
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with no evidence of a statistically significant change in the rate of increase after introduction of the 
varicella vaccination program. Before introduction of this program, HZ incidence was higher in 
women (RR, 1.21 [95% CI, 1.19 to 1.24]) than men and was lower in black persons (RR, 0.51 [CI, 
0.48 to 0.53]) and Hispanic persons (RR, 0.76 [CI, 0.72 to 0.81]) than white persons. In a model 
adjusted for sex, age, and calendar year from 1997 to 2010, HZ incidence did not vary by state 
varicella vaccination coverage (RR, 0.9998 [CI, 0.9993 to 1.0003]).
Limitation—Uncertain level and consistency of health-seeking behavior and access and uncertain 
accuracy of disease coding.
Conclusion—Age-specific HZ incidence increased in the U.S. population older than 65 years 
even before implementation of the childhood varicella vaccination program. Introduction and 
widespread use of the vaccine did not seem to affect this increase. This information is reassuring 
for countries considering universal varicella vaccination.
Primary Funding Source—None.
Primary varicella zoster virus (VZV) infection causes varicella, a contagious rash illness that 
is usually mild in children but can lead to such complications as pneumonia; encephalitis; 
and, rarely, death (1). Infants, adolescents, adults, immunocompromised persons, and 
pregnant women are more susceptible to varicella complications. The congenital varicella 
syndrome is a feared complication of varicella, as well. Reactivation of VZV causes herpes 
zoster (HZ), a painful vesicular eruption occurring unilaterally in 1 or more closely 
overlapping dermatomes. Virtually all adults in the United States have latent VZV infection 
(2), and reactivation causes an estimated 1 million cases of HZ each year (3).
Although HZ can lead to serious ocular and neurologic complications (4), the most common 
complication is postherpetic neuralgia. Approximately 12% to 24% of older adults with HZ 
have persistent pain 90 days or more after onset of rash. This chronic pain can lead to 
substantial distress and functional limitations, with detrimental effects on quality of life (5).
In 1996, the U.S. Advisory Committee on Immunization Practices first recommended 
routine varicella vaccination for children aged 12 to 18 months (6). Vaccination of healthy 
children is routinely recommended in several countries, including Canada, Australia, 
Germany, and South Korea; however, some European countries reserve vaccination for 
susceptible adolescents or adults in whom risk for severe disease is higher or have no routine 
recommendation because of doubts about the importance of the disease burden and about the 
cost-effectiveness of the vaccine (7).
Hope-Simpson (8) hypothesized that exposure to varicella would decrease risk for HZ 
through boosting VZV-specific immunity. Subsequent studies (9–11) have shown decreased 
risk for HZ in adults who live with children or have known varicella contacts; other studies 
(12, 13) have not shown this effect. Mathematical models that incorporate external boosting 
have predicted that introduction of a universal varicella vaccine program for children would 
lead to adults being exposed to children with varicella less frequently and increase HZ 
incidence in adults (9, 14). The U.K. Health Protection Agency has raised concerns that 
adding the varicella vaccine to their childhood immunization program would lead to an 
increase in HZ in adults (15).
Hales et al. Page 2
Ann Intern Med. Author manuscript; available in PMC 2017 December 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
In the United States, several studies spanning 1945 to 2006 have reported increased HZ 
incidence (3, 16–19). Temporal increases in HZ incidence have also been reported in 
countries without a varicella vaccination program (20). However, no studies have shown an 
increase in HZ incidence after varicella vaccination compared with an adequate baseline 
before introduction of the vaccine. In 2006, the U.S. Advisory Committee on Immunization 
Practices recommended HZ vaccination for adults aged 60 years or older to prevent HZ and 
its sequelae (21). However, as of 2010, only 14.4% of adults aged 60 years or older have 
received the vaccine (22).
We used Medicare claims data from 1992 through 2010 to evaluate trends in HZ incidence 
in the U.S. population older than 65 years and determine any influence of the varicella 
vaccination program on these trends. We also examined the influence of age, sex, and race or 
ethnicity on HZ incidence.
Methods
Study Population
We obtained health care claims data on a 5% random sample of Medicare beneficiaries 
maintained in the Centers for Medicare & Medicaid Services Chronic Conditions Data 
Warehouse (23). The study population comprised U.S. residents in the 5% random sample 
who were older than 65 years and had more than 1 calendar year of continuous enrollment in 
Medicare fee-for-service Parts A and B between 1991 and 2010. The data included claims 
generated in outpatient, inpatient, skilled nursing facility, and home health settings. Self-
reported race and ethnicity data come from U.S. Social Security Administration records. 
Mutually exclusive categories included white (non-Hispanic); black (non-Hispanic); 
Hispanic; Asian, Asian American, or Pacific Islander; American Indian or Alaska Native; or 
other (24).
Definition and Calculation of HZ Incidence
We defined incident HZ in a given year as the first occurrence of an International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), code (any 
position) for HZ (053.xx) in any health care setting with no HZ code during the previous 
calendar year. Claims with a code for postherpetic neuralgia (053.12 or 053.13) were 
excluded. We calculated incidence as the number of incident cases of HZ divided by the 
total person-years. Because we required 1 calendar year of enrollment without HZ before 
defining an incident case, the calculation of HZ incidence included beneficiaries beginning 
at age 66 years. We standardized HZ incidence by age and sex using the 2000 U.S. standard 
population (25, 26).
Analysis of HZ Incidence in an Immunocompetent Subgroup
Herpes zoster is more common in immunocompromised persons (21, 27). To exclude the 
possibility that changes in HZ incidence were due to changes in the prevalence of 
immunosuppression, we performed a separate analysis restricted to a selected cohort of 
beneficiaries who were least likely to be immunocompromised. This analysis excluded 
beneficiaries with an ICD-9-CM code indicating any potentially immunocompromising 
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condition or any condition that could potentially be managed with immunosuppressive 
treatments or corticosteroids (Appendix Table, available at www.annals.org) (19). Our 
definition was artificial but ensured that beneficiaries remaining in this analysis were not 
immunocompromised. We standardized HZ incidence in this population by age and sex 
using the 2000 U.S. standard population (25, 26).
Assessing the Effect of Health-Seeking Behavior or Medicare on Temporal Increases in HZ 
Incidence
Because cases of HZ identified through administrative data are medically attended, changes 
in HZ incidence can be due to changes relating to the Medicare program or to health-seeking 
behavior. To control for such changes, we compared trends in incidence of HZ with those of 
10 preselected conditions, which, like HZ, are common and acute and typically managed in 
outpatient settings (19). We identified first instances of HZ and the selected conditions as the 
first occurrence of the corresponding ICD-9-CM codes in outpatient settings in the primary 
or secondary positions, with no code for the condition in the previous 4 calendar years. We 
derived annual incidence standardized by age and sex from the 2000 U.S. standard 
population and calculated ratios of HZ incidence to the incidence of each selected condition.
Analysis of HZ Incidence Trends
We used Poisson regression analysis to compare HZ trends during 3 periods of varicella 
vaccination program implementation: preimplementation (1992 to 1995), early 
implementation (1996 to 1999), and full implementation (2000 to 2010). The model 
included age group, sex, calendar year, indicator variables for implementation period, and 
interactions between calendar year and the indicator variables. We used generalized 
estimating equations (GEEs) to account for correlated data within states. The parameter 
estimates for the interaction terms allow us to compare the annual rate of increase in HZ 
incidence during early and full implementation periods with the rate of increase during the 
preimplementation period (28), adjusting for age and sex.
Assessing Potential Risk Factors for HZ and Influence of State-Level Varicella Vaccination 
Coverage on HZ Incidence
To evaluate risk factors for HZ, we calculated adjusted RRs for age, sex, and race or 
ethnicity using Poisson regression analysis with GEEs to account for correlated data within 
states. We limited this analysis to the period before introduction of the universal varicella 
vaccination program (1992 to 1996) to exclude any possibility of bias due to implementation 
of the program.
We examined the effect of state varicella vaccination coverage on HZ incidence during the 
period after implementation of the varicella vaccination program (1997 to 2010). We 
obtained rates of annual 1-dose varicella vaccination coverage for children aged 19 to 35 
months for each of the 50 states and the District of Columbia from the National 
Immunization Survey (19, 29). We calculated the RR of state vaccine coverage (expressed as 
a percentage) for HZ incidence, adjusted for age, sex, and calendar year by using Poisson 
regression with GEEs to account for statistical dependence of measurements within states. 
To evaluate whether increasing varicella vaccination coverage had a delayed effect on HZ 
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incidence, which previous models (9) suggested, we replaced concurrent vaccination 
coverage with coverage lagged by 10 years and ran the same model.
The Centers for Disease Control and Prevention Human Subjects Coordinator determined 
that this study did not require review for human subjects protections because the data did not 
contain personal identifiers and were not originally collected specifically for this study. We 
used SAS, version 9.3 (SAS Institute, Cary, North Carolina), for all data management and 
statistical analyses. Poisson regression analyses with GEEs were performed using PROC 
GENMOD in SAS software.
Role of the Funding Source
No external funding was obtained for this study.
Results
The study included 2 845 353 Medicare beneficiaries from 1992 through 2010, contributing 
a total of 22 508 343 person-years with a median of 7 years per beneficiary (Table 1). Age 
and sex distributions were similar to the entire Medicare population but with fewer 
beneficiaries in western states and fewer Hispanic and Asian beneficiaries (data not shown). 
The mean age was 76.1 years in 1992 and 77.1 years in 2010.
A total of 281 317 incident cases of HZ occurred. Crude HZ incidence increased 40% from 
10.2 per 1000 person-years in 1992 to 14.3 per 1000 persons in 2010; age- and sex-
standardized HZ incidence increased 39% from 10.0 per 1000 person-years in 1992 to 13.9 
per 1000 person-years in 2010 (Figure). Mean age at the time of HZ diagnosis remained 
stable at 76.9 years in 1992 and 77.9 years in 2010. The exponentiated parameter estimate 
for the interaction between calendar year and the indicator variable for the early varicella 
vaccine implementation period was 1.002 (95% CI, 0.984 to 1.020), indicating that the 
annual rate of increase in HZ incidence during this period (1996 to 1999) was 0.2% higher 
than that during the preimplementation period (1992 to 1995) but was not statistically 
significant. Similarly, the exponentiated parameter estimate for the interaction between 
calendar year and the indicator variable for full implementation period (2000 to 2010) was 
1.008 (CI, 0.994 to 1.023).
Increases occurred among all age groups (Figure), racial or ethnic groups, and census 
divisions (data not shown) and both sexes; they remained apparent even in the selected 30% 
of beneficiaries without a potentially immunocompromising condition (Appendix Figure 1, 
available at www.annals.org). In addition, increases in HZ incidence were greater than those 
seen in 9 out of 10 analogous conditions that we investigated (Appendix Figure 2, available 
at www.annals.org). Table 2 shows data on the incidence of HZ among Medicare 
beneficiaries in 2010 to highlight the incidence of HZ in key subgroups.
We evaluated HZ incidence by sex, age group, and race or ethnicity (Table 3) before 
introduction of the universal varicella vaccination program (1992 to 1996). The RR for 
women was 1.21 (CI, 1.19 to 1.24) and increased for each 5-year age group up to the 80- to 
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84-year group. Compared with white persons, black persons (RR, 0.51 [CI, 0.48 to 0.53]) 
and Hispanic persons (RR, 0.76 [CI, 0.72 to 0.81]) had lower HZ incidence.
In the GEE model adjusted for sex, age, and calendar year, HZ incidence did not vary by 
state varicella vaccination coverage (RR, 0.9998 [CI, 0.9993 to 1.0003]). Varicella 
vaccination coverage lagged by 10 years was also not significant (RR, 1.0010 [CI, 0.9997 to 
1.0022]). Incidence trends of HZ in states with consistently high varicella vaccination 
coverage from 1997 through 2010 (mean coverage, 82%) compared with states with low 
varicella vaccination coverage (mean coverage, 64%) overlapped with no pattern emerging 
(data not shown).
Discussion
Varicella exposure has been postulated to boost VZV-specific immunity and reduce the risk 
for VZV reactivation. Concern has been expressed that routine childhood varicella 
vaccination, introduced in the United States in 1996, could thereby lead to an increase in HZ 
incidence by reducing opportunities for exposure to varicella. Our findings suggest that, 
although HZ incidence has increased in elderly persons, routine varicella vaccination has not 
influenced this increase.
First, the rise in HZ incidence clearly predates 1996 and HZ incidence did not accelerate 
after implementation of the varicella vaccination program, when varicella vaccination 
coverage reached 90% and varicella incidence decreased by 90% (30, 31). Second, state 
varicella vaccination coverage had no effect on HZ incidence concurrently or 10 years later. 
Finally, the mean age at the time of HZ diagnosis did not decrease during the study, which 
might occur if external boosting helped to maintain protection. Thus, although HZ incidence 
has increased in the elderly population, we did not find evidence to suggest that this increase 
has been influenced by the varicella vaccination program in the United States. This finding 
confirms the results of other studies before and after introduction of the varicella vaccine 
(19, 32–34).
The lack of evidence for an effect of the varicella vaccination program on HZ incidence 
might be explained in several ways. First, although some studies suggest that exposure to 
varicella protects against HZ (9–11), other findings contradict this (12, 13). Because latent 
VZV can reactivate subclinically and boost immunity (35–37), compensatory boosting might 
occur among persons who are not periodically exposed to varicella (8). Alternatively, 
external boosting might require a degree of varicella exposure that is uncommon among 
elderly persons, particularly because this population has less-frequent exposure to children 
than do younger adults (38).
Age- and sex-standardized HZ incidence among elderly persons increased 39% from 10.0 
per 1000 person-years to 13.9 per 1000 person-years during the 19-year study. On the basis 
of our observed values, we calculate that 14% of men and 20% of women who reach age 65 
years will have HZ during their remaining lifetime (39). The observed increase is robust, 
occurring among all age, sex, and race or ethnicity subgroups and all geographic regions. It 
does not seem to be an artifact of changing prevalence of immunocompromising conditions, 
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because increases in age- and sex-standardized HZ incidence are seen even after restricting 
the analysis to a selected cohort of immunocompetent persons. Furthermore, increases in HZ 
incidence persisted when it was compared with 9 of 10 other acute outpatient conditions, 
suggesting that these increases were not due to underlying changes in health-seeking 
behavior or in the Medicare program over time.
Increases in HZ incidence in the elderly population have been reported in several studies in 
countries with and without varicella vaccination programs (3, 16, 17, 19, 20, 40, 41); 
however, other studies have not shown an increase (32, 33). We have no explanation for the 
trend and expect that it awaits a better understanding of why a substantial minority of 
persons have HZ during their lifetime, whereas most do not. In particular, chronic diseases 
prevalent among elderly persons do not explain most cases of HZ (42).
Data from the large, generalizable Medicare population provide an opportunity to more 
precisely characterize the well-recognized effect of age on HZ incidence. Although the 
association between HZ incidence and age seems to plateau after age 80 years, the risk for 
postherpetic neuralgia, hospitalization, and other complications continues to increase with 
age. We also provide precise data to confirm that older women are at greater risk for HZ than 
older men; most studies report increased HZ incidence among women in most age cohorts, 
including children, although the reason remains unknown (3, 17, 18, 20, 41, 43–47). Finally, 
we provide data that black and Hispanic persons are at lower risk for HZ than white persons. 
A few reports are available on the reduced risk for HZ among black persons (43, 45, 48), 
although data about HZ incidence in Hispanic persons are lacking (13). The RR for 
American Indians or Alaska Natives should be interpreted with caution because health 
services provided by the Indian Health Service were not fully captured in the Medicare data 
(49).
We followed elderly Medicare beneficiaries who are at high risk for HZ for a long period 
spanning the licensure of varicella vaccination. In 2006, the U.S. Advisory Committee on 
Immunization Practices recommended the HZ vaccine for adults aged 60 years or older for 
prevention of HZ and its sequelae (21). Uptake of the HZ vaccine has been slow, with only 
1.9% coverage in adults aged 60 years or older in 2007 (50), increasing to 14.4% in 2010 
(22).
Although we do not expect that such low coverage would substantially affect HZ incidence 
on a population level, these data provide a baseline for monitoring effects of the HZ vaccine 
program as coverage increases. A previous study of HZ incidence in all ages from 1993 to 
2006 using MarketScan (Truven Health Analytics, Ann Arbor, Michigan), a database of 
health care claims from commercial insurers, had limitations in evaluating trends in adults 
aged 65 years or older because the size of the study population in this age group changed 
substantially over the observation period, allowing opportunities for unmeasured 
confounding (19). MarketScan did not incorporate Medicare data until 1996 and even then 
contained health care claims for only the selected subset of Medicare beneficiaries with 
managed care. The Centers for Medicare & Medicaid Services Chronic Conditions Data 
Warehouse used in this study contains claims for a stable and more representative population 
of beneficiaries in traditional fee-for-service Medicare during the study period.
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The use of administrative data has limitations. The accuracy of findings from studies based 
on health care claims depends on high and consistent levels of health-seeking behavior and 
access and on accurate disease coding. These criteria are probably met for most cases of HZ 
because it is painful and the study population had Medicare Parts A and B coverage for 
health care costs; however, mild cases may not come to medical attention, resulting in an 
underestimate of true incidence of HZ. In a population-based survey of 141 adults aged 60 
years or older who had had HZ, 95% sought medical attention (50).
Differences in health-seeking behavior or access may explain a portion of the variation in 
risk by sex or race or ethnicity. We could not directly assess the accuracy of HZ claims in 
our data through record reviews. However, previous studies of HZ have shown good 
concordance between coding and actual health care visits, with positive predictive values 
ranging from 85% to 100% (12, 18, 51). Furthermore, estimates from self-reports and health 
care settings of HZ incidence have been similar to ours, providing reassurance about the 
sensitivity of HZ coding (17).
Our study was also limited by the data available for analysis. Although more than one half of 
cases of HZ in the United States occur in persons younger than 65 years and therefore were 
missed by our Medicare analysis, HZ tends to be much more severe in older adults; thus, the 
Medicare population is of particular importance (3). We showed that HZ incidence was not 
affected by state-level variation in varicella vaccination coverage controlled for sex and age 
but were not able to consider other factors that vary across states and might affect HZ 
incidence, such as age at parenthood, family size, or living with young children.
Age-specific HZ incidence has been increasing in the U.S. population older than 65 years 
even before implementation of the childhood varicella vaccination program. Introduction 
and widespread use of this vaccine did not seem to affect this increase. This information is 
reassuring for countries considering universal varicella vaccination.
Our findings have several implications. First, in the absence of explanations for increasing 
HZ incidence, properly monitoring the effect of the HZ vaccination program or projecting 
future HZ incidence will be difficult. Furthermore, HZ poses a substantial burden of disease 
in the elderly population; continued increases in HZ incidence would be worrisome and need 
to be understood. Fortunately, an effective vaccine is now available that can help prevent this 
disabling disease.
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Context
The incidence of herpes zoster (HZ) in older adults is increasing. This could be due to 
routine childhood varicella vaccination, which prevents adults from experiencing a 
natural boost in varicella-specific immunity through exposure to children with 
chickenpox.
Contribution
Information from a Medicare database showed that the age-specific increase in HZ 
incidence began before the introduction of routine childhood varicella vaccination and 
does not vary by state vaccination coverage in models adjusted for sex, age, and calendar 
year.
Implication
The age-specific increase in HZ incidence in older adults is currently unexplained and 
argues for wider use of HZ vaccination in this population.
—The Editors
Hales et al. Page 12
Ann Intern Med. Author manuscript; available in PMC 2017 December 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. HZ incidence among Medicare beneficiaries older than 65 years, by age group, 1992–
2010
HZ = herpes zoster.
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Appendix Figure 1. Age- and sex-standardized HZ incidence among immunocompetent 
Medicare beneficiaries older than 65 years, 1992–2010
This immunocompetent subpopulation excluded beneficiaries with any International 
Classification of Diseases, Ninth Revision, Clinical Modification, code indicating a 
potentially immunocompromising condition or a condition that may be managed with 
immunosuppressive treatment (see Appendix Table for the list of codes). HZ = herpes zoster.
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Appendix Figure 2. Age- and sex-standardized ratios of HZ incidence to the incidence of 10 
selected conditions, 1995–2010
The 10 conditions and associated International Classification of Diseases, Ninth Revision, 
Clinical Modification, codes were impacted cerumen (380.4), calculus of kidney and ureter 
(592.x), urinary tract infection (599.0), ingrowing nail (703.0), lipoma (214.x), sprains and 
strains of wrist and hand (842.xx), inflammation of eyelids (373.xx), epistaxis (784.7), 
hemorrhoids (455.x), and gout (274.0, 274.9). HZ = herpes zoster.
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Table 1
Demographic Characteristics of Medicare Beneficiaries (Selected Years)
Variable 1995 2000 2005 2010
Person-years 1 231 976 1 128 712 1 235 751 1 135 298
Sex, n (%)
 Men 483 817 (39.3) 441 526 (39.1) 501 394 (40.6) 470 528 (41.4)
 Women 748 158 (60.7) 687 186 (60.9) 734 356 (59.4) 664 770 (58.6)
Age group, n (%)
 66–69 y* 226 133 (18.4) 178 631 (15.8) 214 373 (17.3) 208 882 (18.4)
 70–74 y 358 162 (29.1) 306 463 (27.2) 313 114 (25.3) 287 926 (25.4)
 75–79 y 279 392 (22.7) 274 404 (24.3) 283 874 (23.0) 234 389 (20.6)
 80–84 y 195 768 (15.9) 191 992 (17.0) 222 579 (18.0) 195 137 (17.2)
 ≥85 y 172 521 (14.0) 177 223 (15.7) 201 811 (16.3) 208 964 (18.4)
Race/ethnicity, n (%)
 White (non-Hispanic) 1 099 459 (89.2) 1 002 902 (88.9) 1 087 942 (88.0) 993 568 (87.5)
 Black (non-Hispanic) 94 718 (7.7) 84 891 (7.5) 95 728 (7.7) 83 773 (7.4)
 Hispanic 15 605 (1.3) 16 483 (1.5) 18 727 (1.5) 18 038 (1.6)
 Asian, Asian American, or Pacific Islander 8587 (0.7) 11 693 (1.0) 16 218 (1.3) 19 112 (1.7)
 American Indian or Alaska Native 2919 (0.2) 3712 (0.3) 4407 (0.4) 4500 (0.4)
 Other 6012 (0.5) 6629 (0.6) 11 322 (0.9) 15 304 (1.3)
 Unknown 4676 (0.4) 2403 (0.2) 1408 (0.1) 1006 (0.1)
*
Because we required 1 calendar year of enrollment without herpes zoster before defining an incident case, the calculation of herpes zoster 
incidence included beneficiaries beginning at age 66 y.
Ann Intern Med. Author manuscript; available in PMC 2017 December 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Hales et al. Page 17
Table 2
Crude HZ Incidence Among Medicare Beneficiaries, by Sex, Age Group, and Race/Ethnicity, 2010
Variable Events, n Person-Years of Exposure HZ Incidence per 1000 Person-Years (95% CI)*
Sex
 Men 5625 470 528 12.0 (11.6–12.3)
 Women 10 550 664 770 15.9 (15.6–16.2)
Age group
 66–69 y 2366 208 882 11.3 (10.9–11.8)
 70–74 y 3835 287 926 13.3 (12.9–13.7)
 75–79 y 3463 234 389 14.8 (14.3–15.3)
 80–84 y 3074 195 137 15.8 (15.2–16.3)
 ≥ 85 y 3437 208 964 16.4 (15.9–17.0)
Race/ethnicity
 White (non-Hispanic) 14 675 993 568 14.8 (14.5–15.0)
 Black (non-Hispanic) 692 83 772 8.3 (7.7–8.9)
 Hispanic 238 18 038 13.2 (11.6–15.0)
 Asian, Asian American, or Pacific Islander 279 19 110 14.6 (13.0–16.4)
 American Indian or Alaska Native 74 4500 16.4 (13.1–20.6)
 Other 204 15 304 13.3 (11.6–15.3)
 Unknown 13 1006 12.9 (7.6–22.0)
Total 16 175 1 135 298 14.2 (14.0–14.5)
HZ = herpes zoster.
*CIs calculated using the Wilson score method.
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Table 3
Risk for HZ Among U.S. Medicare Recipients Older Than 65 Years, 1992–1996
Variable Unadjusted RR (95% CI) Adjusted RR (95% CI)
Sex
 Men 1.00 (reference) 1.00 (reference)
 Women 1.24 (1.22–1.26) 1.21 (1.19–1.24)
Age group
 66–69 y 1.00 (reference) 1.00 (reference)
 70–74 y 1.18 (1.14–1.21) 1.17 (1.13–1.21)
 75–79 y 1.35 (1.31–1.39) 1.33 (1.29–1.37)
 80–84 y 1.49 (1.44–1.54) 1.45 (1.40–1.50)
 ≥85 y 1.48 (1.44–1.52) 1.42 (1.38–1.46)
Race/ethnicity
 White (non-Hispanic) 1.00 (reference) 1.00 (reference)
 Black (non-Hispanic) 0.51 (0.48–0.54) 0.51 (0.48–0.53)
 Hispanic 0.73 (0.69–0.77) 0.76 (0.72–0.81)
 Asian, Asian American, or Pacific Islander 0.90 (0.75–1.08) 0.92 (0.76–1.12)
 American Indian or Alaska Native 0.61 (0.44–0.85) 0.60 (0.43–0.84)
 Other 0.97 (0.84–1.11) 0.96 (0.84–1.11)
 Unknown 1.09 (0.98–1.20) 0.96 (0.86–1.07)
HZ = herpes zoster; RR = rate ratio.
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Appendix Table
ICD-9-CM Codes Indicating a Potentially Immunocompromising Condition or a Condition That May Be 
Managed With Immunosuppressive Treatments or Corticosteroids
ICD-9-CM Code Description
010.xx Primary tuberculous infection
011.xx Pulmonary tuberculosis
012.xx Other respiratory tuberculosis
013.xx Tuberculosis of meninges and central nervous system
014.xx Tuberculosis of intestines, peritoneum, and mesenteric glands
015.xx Tuberculosis of bones and joints
016.xx Tuberculosis of genitourinary system
017.xx Tuberculosis of other organs
018.xx Miliary tuberculosis
023.x Brucellosis
030.x Brucellosis
042 Leprosy
056.71 Arthritis due to rubella
075 Infectious mononucleosis
079.53 HIV, type 2 (HIV-2)
083.x Other rickettsioses
088.81 Lyme disease
099.3 Reiter disease
115.xx Histoplasmosis
117.3 Aspergillosis
123.x Other cestode infection
124 Trichinosis
130.x Toxoplasmosis
133.x Acariasis
135 Sarcoidosis
136.1 Behçet syndrome
136.5 Sarcosporidiosis
140.x Malignant neoplasm of lip
141.x Malignant neoplasm of tongue
142.x Malignant neoplasm of major salivary glands
143.x Malignant neoplasm of gum
144.x Malignant neoplasm of floor of mouth
145.x Malignant neoplasm of other and unspecified parts of mouth
146.x Malignant neoplasm of oropharynx
147.x Malignant neoplasm of nasopharynx
148.x Malignant neoplasm of hypopharynx
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ICD-9-CM Code Description
149.x Malignant neoplasm of other and ill-defined sites within the lip, oral cavity, and pharynx
150.x Malignant neoplasm of esophagus
151.x Malignant neoplasm of stomach
152.x Malignant neoplasm of small intestine, including duodenum
153.x Malignant neoplasm of colon
154.x Malignant neoplasm of rectum, rectosigmoid junction, and anus
155.x Malignant neoplasm of liver and intrahepatic bile ducts
156.x Malignant neoplasm of gallbladder and extrahepatic bile ducts
157.x Malignant neoplasm of pancreas
158.x Malignant neoplasm of retroperitoneum and peritoneum
159.x Malignant neoplasm of other and ill-defined sites within the digestive organs and peritoneum
160.x Malignant neoplasm of nasal cavities, middle ear, and accessory sinuses
161.x Malignant neoplasm of larynx
162.x Malignant neoplasm of trachea, bronchus, and lung
163.x Malignant neoplasm of pleura
164.x Malignant neoplasm of thymus, heart, and mediastinum
165.x Malignant neoplasm of other and ill-defined sites within the respiratory system and intrathoracic organs
170.x Malignant neoplasm of bone and articular cartilage
171.x Malignant neoplasm of connective and other soft tissue
172.x Malignant melanoma of skin
174.x Malignant neoplasm of female breast
175.x Malignant neoplasm of male breast
176.x Kaposi sarcoma
179 Malignant neoplasm of uterus, part unspecified
180.x Malignant neoplasm of cervix uteri
181 Malignant neoplasm of placenta
182.x Malignant neoplasm of body of uterus
183.x Malignant neoplasm of ovary and other uterine adnexa
184.x Malignant neoplasm of other and unspecified female genital organs
185 Malignant neoplasm of prostate
186.x Malignant neoplasm of testis
187.x Malignant neoplasm of penis and other male genital organs
188.x Malignant neoplasm of bladder
189.x Malignant neoplasm of kidney and other and unspecified urinary organs
190.x Malignant neoplasm of eye
191.x Malignant neoplasm of brain
192.x Malignant neoplasm of other and unspecified parts of nervous system
193 Malignant neoplasm of thyroid gland
194.x Malignant neoplasm of other endocrine glands and related structures
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ICD-9-CM Code Description
195.x Malignant neoplasm of other and ill-defined sites
196.x Secondary and unspecified malignant neoplasm of lymph nodes
197.x Secondary malignant neoplasm of respiratory and digestive systems
198.xx Secondary malignant neoplasm of other specified sites
199.x Malignant neoplasm without specification of site
200.xx Lymphosarcoma and reticulosarcoma and other specified malignant tumors of lymphatic tissue
201.xx Hodgkin disease
202.xx Other malignant neoplasms of lymphoid and histiocytic tissue
203.xx Multiple myeloma and immunoproliferative neoplasms
204.xx Lymphoid leukemia
205.xx Myeloid leukemia
206.xx Monocytic leukemia
207.xx Other specified leukemia
208.xx Leukemia of unspecified cell type
209.xx Neuroendocrine tumors
212.6 Benign neoplasm of thymus
228.xx Hemangioma and lymphangioma, any site
235.x Neoplasm of uncertain behavior of digestive and respiratory systems
236.xx Neoplasm of uncertain behavior of genitourinary organs
237.xx Neoplasm of uncertain behavior of endocrine glands and nervous system
238.xx Neoplasm of uncertain behavior of other and unspecified sites and tissues
239.xx Neoplasms of unspecified nature
242.xx Thyrotoxicosis with or without goiter
245.x Thyroiditis
250.xx Diabetes mellitus
251.1 Other specified hypoglycemia
252.1 Other disorders of pancreatic internal secretion
255.0 Cushing syndrome
255.1x Hyperaldosteronism
255.2 Adrenogenital disorders
255.4x Corticoadrenal insufficiency
256.3x Other ovarian failure
258.1 Other combinations of endocrine dysfunction
258.8 Other specified polyglandular dysfunction
258.9 Polyglandular dysfunction, unspecified
265.2 Pellagra
273.x Disorders of plasma protein metabolism
274.xx Gout
275.4x Disorders of calcium metabolism
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ICD-9-CM Code Description
277.00 Cystic fibrosis without mention of meconium ileus
277.01 Cystic fibrosis with meconium ileus
277.3x Amyloidosis
277.86 Other specified disorders of metabolism, peroxisomal disorders
277.89 Other specified disorders of metabolism
279.xx Disorders involving the immune mechanism
283.xx Acquired hemolytic anemias
284.xx Aplastic anemia and other bone marrow failure syndromes
286.5 Hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies or inhibitors
286.6 Defibrination syndrome
287.0 Allergic purpura
287.3x Primary thrombocytopenia
287.4x Secondary thrombocytopenia
288.xx Diseases of white blood cells
289.4 Hypersplenism
289.50 Disease of spleen, unspecified
289.51 Chronic congestive splenomegaly
289.52 Splenic sequestration
289.59 Other diseases of spleen, other
289.81 Primary hypercoagulable state
289.82 Secondary hypercoagulable state
289.89 Other specified diseases of blood and blood-forming organs
289.9 Unspecified diseases of blood and blood-forming organs
291.xx Alcohol-induced mental disorders
303.xx Alcohol dependence syndrome
333.5 Other choreas
334.0 Friedreich ataxia
334.8 Other spinocerebellar diseases
337.0x Idiopathic peripheral autonomic neuropathy
337.2x Reflex sympathetic dystrophy
340 Multiple sclerosis
341.xx Other demyelinating diseases of central nervous system
345.6x Infantile spasms
346.2x Variants of migraine, not elsewhere classified
348.2 Benign intracranial hypertension
348.5 Cerebral edema
351.0 Bell palsy
351.8 Other facial nerve disorders
351.9 Facial nerve disorder, unspecified
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ICD-9-CM Code Description
354.x Mononeuritis of upper limb and mononeuritis multiplex
357.xx Inflammatory and toxic neuropathy
358.xx Myoneural disorders
359.6 Symptomatic inflammatory myopathy in diseases classified elsewhere
359.8x Other myopathies
360.11 Sympathetic uveitis
362.18 Retinal vasculitis
362.50 Macular degeneration (senile), unspecified
362.52 Nonexudative senile macular degeneration
363.0x Focal chorioretinitis and focal retinochoroiditis
363.1x Disseminated chorioretinitis and disseminated retinochoroiditis
363.2x Other and unspecified forms of chorioretinitis and retinochoroiditis
364.0x Acute and subacute iridocyclitis
364.1x Chronic iridocyclitis
364.2x Certain types of iridocyclitis
364.3 Unspecified iridocyclitis
364.4x Vascular disorders of iris and ciliary body
370.xx Keratitis
372.05 Acute atopic conjunctivitis
372.14 Other chronic allergic conjunctivitis
377.3x Optic neuritis
379.0x Scleritis and episcleritis
381.xx Nonsuppurative otitis media and Eustachian tube disorders
386.0x Ménière disease
386.3x Labyrinthitis
391.x Rheumatic fever with heart involvement
392.0 Rheumatic chorea with heart involvement
392.9 Rheumatic chorea without mention of heart involvement
411.xx Other acute and subacute forms of ischemic heart disease
420.xx Acute pericarditis
422.xx Acute myocarditis
425.5 Alcoholic cardiomyopathy
429.4 Functional disturbances following cardiac surgery
446.xx Polyarteritis nodosa and allied conditions
464.4 Croup
471.x Nasal polyps
477.x Allergic rhinitis
478.8 Upper respiratory tract hypersensitivity reaction, site unspecified
491.21 Obstructive chronic bronchitis with (acute) exacerbation
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ICD-9-CM Code Description
493.xx Asthma
495.x Extrinsic allergic alveolitis
503 Pneumoconiosis due to other inorganic dust
507.x Pneumonitis due to solids and liquids
516.x Other alveolar and parietoalveolar pneumonopathy
518.3 Pulmonary eosinophilia
528.2 Oral aphthae
528.9 Other and unspecified diseases of the oral soft tissues
530.1x Esophagitis
535.3x Alcoholic gastritis
555.x Regional enteritis
556.x Ulcerative colitis
570 Acute and subacute necrosis of liver
571.0 Alcoholic fatty liver
571.1 Acute alcoholic hepatitis
571.2 Alcoholic cirrhosis of liver
571.3 Alcoholic liver damage, unspecified
571.4x Chronic hepatitis
571.5 Cirrhosis of liver without mention of alcohol
571.6 Biliary cirrhosis
576.1 Cholangitis
579.0 Celiac disease
579.1 Tropical sprue
579.8 Other specified intestinal malabsorption
580.xx Acute glomerulonephritis
581.xx Nephrotic syndrome
583.xx Nephritis and nephropathy, not specified as acute or chronic
585.x Chronic kidney disease
586 Renal failure, unspecified
592.x Calculus of kidney and ureter
683 Acute lymphadenitis
690.xx Erythematosquamous dermatosis
691.x Atopic dermatitis and related conditions
692.xx Contact dermatitis and other eczema
694.xx Bullous dermatoses
695.xx Erythematous conditions
696.x Psoriasis and similar disorders
697.x Lichen
698.2 Lichen
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ICD-9-CM Code Description
698.3 Lichenification and lichen simplex chronicus
701.x Other hypertrophic and atrophic conditions of skin
704.01 Alopecia areata
706.1 Other acne
706.2 Sebaceous cyst
708.x Urticaria
710.x Diffuse diseases of connective tissue
711.5x Arthropathy associated with other viral diseases
712.xx Crystal arthropathies
713.6 Arthropathy associated with hypersensitivity reaction
714.xx Rheumatoid arthritis and other inflammatory polyarthropathies
715.2x Osteoarthrosis, localized, secondary
716.1x Traumatic arthropathy
720.xx Ankylosing spondylitis and other inflammatory spondylopathies
721.xx Spondylosis and allied disorders
722.xx Intervertebral disc disorders
723.x Other disorders of cervical region
724.xx Other and unspecified disorders of back
725 Polymyalgia rheumatica
726.xx Peripheral enthesopathies and allied syndromes
727.xx Other disorders of synovium, tendon, and bursa
728.89 Other disorders of muscle, ligament, and fascia, other
733.99 Disorder of bone and cartilage, unspecified, other
746.1 Tricuspid atresia and stenosis, congenital
756.5x Osteodystrophies
759.5 Tuberous sclerosis
795.71 Nonspecific serologic evidence of HIV
802.6 Fracture of orbital floor (blow-out), closed
802.7 Fracture of orbital floor (blow-out), open
848.5 Other and ill-defined sprains and strains of pelvis
919.4 Insect bite, nonvenomous, without mention of infection
993.0 Barotrauma, otitic
993.3 Caisson disease
995.0 Other anaphylactic reaction
995.1 Angioneurotic edema
995.2x Other and unspecified adverse effect of drug, medicinal and biological substance
995.3 Allergy, unspecified
996.8x Complications of transplanted organ
999.5 Other serum reaction
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ICD-9-CM Code Description
E905.x Venomous animals and plants as the cause of poisoning and toxic reactions
E933.1 Antineoplastic and immunosuppressive drugs
V08 Asymptomatic HIV infection status
V42.xx Organ or tissue replaced by transplant
V58.0 Radiotherapy
V58.11 Encounter for antineoplastic chemotherapy
V58.12 Encounter for antineoplastic immunotherapy
V58.65 Long-term (current) use of steroids
ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification.
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